Pfizer presented these results for abrocitinib at the recent European Academy of Dermatology and Venerology congress in Madrid, Spain. Credit: Shutterstock.

Pfizer has announced promising results from its Phase III JADE MONO-1 study of janus kinase 1 (JAK1) inhibitor abrocitinib in atopic dermatitis.

In the study, abrocitinib met all of its co-primary and secondary endpoints, related to skin clearance and itch relief.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The co-primary endpoints were the proportion of patients who achieved a score of zero for clear or one for almost clear according to the Investigator Global Assessment (IGA) of skin clarity – as well as two-point or greater improvement from their IGA baseline score – and a 75% or greater change from baseline in the Eczema Area and Severity Index (EASI-75).

By week 12, 43.8% of the 200mg dose group of abrocitinib and 23.7% of the 100mg dose group achieved the IGA response rate, compared to 7.9% of the placebo group. In addition, by the same point, 62.7% of the 200mg group and 39.7% of the 100mg group had achieved EASI-75%, compared to 11.8% of the control group.

Secondary endpoints in JADE MONO-1 were at least a four-point reduction in itch severity, as measured by the pruritus numerical rating scale (NRS) and a 90% or greater change in EASI score (EASI-90).

At week 12, 57.2% of the 200mg dose group, 37.7% of the 100mg group, compared to 15.3% for placebo, achieved a more than four-point improvement in NRS. While EASI-90 results at week 12 were 38.6% for 200mg dose of abrocitinib, 18.6% for 100mg and 5.3% for placebo.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The study’s safety data for abrocitinib was consistent with the companion JADE MONO-2, which is also part of the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) development programme.

Pfizer chief development officer of inflammation and immunology Michael Corbo said: “There is a critical need for additional treatment options for patients living with moderate to severe atopic dermatitis.

“We are pleased by these findings, which together with the recently reported positive top-line results from our second Phase III trial, encourage us that, if approved, abrocitinib may provide the first oral, once-daily treatment option for these patients.”

These results were presented at the recent European Academy of Dermatology and Venerology congress in Madrid, Spain.